Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematolo...
05 Décembre 2015 - 2:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced the
presentation of new results from clinical and non-clinical studies
of two of its investigational pipeline products – the Factor Xa
inhibitor reversal agent andexanet alfa and the oral, dual Syk/JAK
kinase inhibitor cerdulatinib – at the 57th American Society of
Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla.
Andexanet alfa, a U.S. Food and Drug Administration
(FDA)-designated breakthrough therapy, is a recombinant protein
specifically designed to reverse the anticoagulant activity of both
direct and indirect Factor Xa inhibitors. Portola is developing it
as a universal reversal agent for patients anticoagulated with an
oral or injectable Factor Xa inhibitor who experience a serious
uncontrolled bleeding event or who require urgent or emergent
surgery. Cerdulatinib inhibits two key cell signaling pathways that
promote cancer cell growth in certain hematologic malignancies.
Portola is developing it to treat patients with hematologic
cancers, specifically those who have relapsed or who have not
responded to prior therapies.
The abstracts are now available at http://www.hematology.org.
All posters will be presented in Hall A of the Orange County
Convention Center.
Andexanet Alfa
- Abstract Title (#1135): Pharmacokinetic and
Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa
Dose to Reverse the Anticoagulant Activity of Direct Fxa
InhibitorsPresenting Author: Janet Leeds, Ph.D.,
senior director, DMPK at PortolaPoster Session
Title: 332. Antithrombotic Therapy: Poster
IPresentation Date and Time: Saturday, December 5:
5:30-7:30 p.m.
- Abstract Title (#2329): Reversal of
Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal
Antidote for Factor Xa InhibitorsPresenting
Author: Genmin Lu, Ph.D., senior scientist at Portola
Poster Session Title: 332. Antithrombotic Therapy:
Poster IIPresentation Date and Time: Sunday,
December 6: 6:00-8:00 p.m.
Cerdulatinib
- Abstract Title
(#1716): The SykJak
Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical
Activity in Chronic Lymphocytic Leukemia By Antagonizing B Cell
Receptor and Micro-environmental SignalingPresenting
Author: Andrew Steele BSc (Hons), M.Phil., Ph.D.,
University of Southampton, U.K.Poster Session
Title: 641. CLL: Biology and Pathophysiology, excluding
Therapy: Poster IPresentation Date and Time:
Saturday, December 5: 5:30-7:30 p.m.
- Abstract Title (#3929): Clinical and
Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070),
a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B
Cell MalignanciesPresenting Author: Paul Hamlin,
M.D., Memorial Sloan-Kettering Cancer CenterPoster Session
Title: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical
Models: Poster IIIPresentation Date and Time:
Monday, December 7, 6:00-8:00 p.m.
- Abstract Title (#3706): Predicting
Cerdulatinib Therapeutic Concentrations in Patients with
Relapsed/Refractory B Cell Malignancies Using Preclinical Models
and Clinical PK/PD and Tumor Response CorrelatesPresenting
Author: Greg Coffey, Ph.D., senior scientist in biology at
PortolaPoster Session Title: 605. Molecular
Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster
IIIPresentation Date and Time: Monday, December 7,
6:00-8:00 p.m.
About Portola Pharmaceuticals, Inc.Portola
Pharmaceuticals is a biopharmaceutical company developing product
candidates that could significantly advance the fields of
thrombosis and other hematologic diseases. The Company is advancing
its three wholly-owned programs using novel biomarker and genetic
approaches that may increase the likelihood of clinical, regulatory
and commercial success of its potentially life-saving therapies.
These programs include betrixaban, an oral, once-daily Factor Xa
inhibitor being evaluated in the APEX Phase 3 study for prophylaxis
of venous thromboembolism; andexanet alfa, a recombinant protein
designed to reverse the anticoagulant effect in patients treated
with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a
Syk/JAK inhibitor in development to treat hematologic cancers.
Portola's partnered program is focused on developing selective Syk
inhibitors for inflammatory conditions. For more information, visit
www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Forward-looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the likelihood of clinical,
regulatory and commercial success of our product candidates. Risks
that contribute to the uncertain nature of the forward-looking
statements include: the accuracy of Portola's estimates regarding
its ability to initiate and/or complete its clinical trials; the
success of Portola's clinical trials and the demonstrated efficacy
of Portola's product candidates to the satisfaction of regulatory
authorities; the accuracy of Portola's estimates regarding its
expenses and capital requirements; regulatory developments in the
United States and foreign countries; Portola's ability to obtain
and maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel.
These and other risks and uncertainties are described more fully in
Portola's most recent filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K, which was
filed on March 2, 2015, and Quarterly Report on Form 10-Q, which
was filed on November 9, 2015. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Portola undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur